fda drug shortages tirzepatide zepbound shortage status 2025 Lilly's weight-loss removed from FDA's list GLP-1 Drugs: FDA Removes Lilly's

In a recent study, patients taking Semaglutide achieved an average weight loss of 15.2% over one year, while those taking Tirzepatide experienced an average weight loss of 15.7%

Cell Metab (2014) 19(6):10507

Shorter studies (single dose or 1 month) have generally shown little to no effect [1][12]

For patients with normal baseline liver function , routine monitoring of LFTs is not specifically mandated by current UK prescribing guidelines

Healthy fats from sources like avocados, nuts, seeds, and olive oil support nutrient absorption and hormone production, though portions should be controlled due to their caloric density